CanSino Biologics leads China in Covid-19 vaccine race
A U.S.-China Covid-19 vaccine race is on.
While U.S. companies including Moderna and Inovio try to develop vaccine candidates against the disease, China’s National Medical Products Administration (NMPA) has given the green light to Tianjin-based CanSino Biologics to launch the country’s first Phase 1 clinical trial for its own vaccine candidate.
Unlike Moderna, which just began its mRNA vaccine trial, CanSino is using a recombinant adenovirus type 5 vector to express the SARS-CoV-2 spike protein to trigger an immune response in the body. The vaccine candidate is known as Ad5-nCoV.
The Hong Kong-listed biotech is co-developing its candidate with the Institute of Biotechnology at China’s Academy of Military Medical Sciences. The two previously worked together to develop an Ebola vaccine, which was approved by Chinese regulators in 2017.
Funded by the government, CanSino’s trial will evaluate the safety and tolerability of the Ad5-nCoV vaccine in three groups of healthy adults receiving different doses, according to study details from the Chinese Clinical Trial Registry.
Apart from CanSino, nine other Covid-19 vaccine development
programs are said to be underway in China. These include collaborations with Chinese biotechs such as Fosun Pharma, CC-Pharming, and Clover Biopharmaceuticals.
“A race is on to bring the world a vaccine or treatment for Covid-19. Chinese companies like CanSino are in the middle of it, and credit to them for making quick work of the development. I’d expect to see more programs enter clinical trials in China in short order,” Brad Loncar, CEO of Loncar Investments, told STAT.
While U.S. companies including Moderna and Inovio try to develop vaccine candidates against the disease, China’s National Medical Products Administration (NMPA) has given the green light to Tianjin-based CanSino Biologics to launch the country’s first Phase 1 clinical trial for its own vaccine candidate.
Unlike Moderna, which just began its mRNA vaccine trial, CanSino is using a recombinant adenovirus type 5 vector to express the SARS-CoV-2 spike protein to trigger an immune response in the body. The vaccine candidate is known as Ad5-nCoV.
The Hong Kong-listed biotech is co-developing its candidate with the Institute of Biotechnology at China’s Academy of Military Medical Sciences. The two previously worked together to develop an Ebola vaccine, which was approved by Chinese regulators in 2017.
Funded by the government, CanSino’s trial will evaluate the safety and tolerability of the Ad5-nCoV vaccine in three groups of healthy adults receiving different doses, according to study details from the Chinese Clinical Trial Registry.
Apart from CanSino, nine other Covid-19 vaccine development
programs are said to be underway in China. These include collaborations with Chinese biotechs such as Fosun Pharma, CC-Pharming, and Clover Biopharmaceuticals.
“A race is on to bring the world a vaccine or treatment for Covid-19. Chinese companies like CanSino are in the middle of it, and credit to them for making quick work of the development. I’d expect to see more programs enter clinical trials in China in short order,” Brad Loncar, CEO of Loncar Investments, told STAT.
.png)
No hay comentarios:
Publicar un comentario